Dear Colleague,
Leading innovations in biotech advancement and discovery are found within
academic institutions and emerging companies. These organizations play an
increasingly important role, both in the U.S. and around the world, in
developing new drug therapies for the treatment of diseases ranging from
Alzheimer’s to cancer to cystic fibrosis to HIV/AIDS and many others. Their role
in researching new therapies is instrumental in developing the next phase of
disease treatment.
A gulf exists between early research and commercial drug development. What is
considered adequately researched at an academic level is vastly different than
what is required on a commercial level. A lack of funding limits the resources
many universities are able to devote to advancing new therapies and such efforts
are typically beyond their core academic missions. The next steps in drug
advancements are both challenging and expensive including advanced clinical
trials up to the marketing of successful therapies, requiring significant
investments. An era of biotech business paradigm shifts requires a new
understanding among the various market segments.
Bridging the gulf requires a dialogue among academic, investment and commercial
organizations.
GTC’s Biotechnology Transfer & Commercialization Conference will bring
together the players needed to move the industry forward. Leading universities,
pharmaceutical companies, venture capital, foundations and biotech companies
will come together to share their perspectives, discuss new models of
cooperation and develop the business relationships that get deals done. Together
they will create new technologies, new companies and new medicines.This
Conference is part of the
8th Modern Drug Discovery and Development Summit. Other conference
tracks include:
9th Stem Cell Research and Therapeutics Conference
7th Assay and Drug Discovery Technologies Conference
4th Translational Medicine Conference
3rd Pharmacokinetics and Pharmacodynamics Conference
Best regards,
2012 Biotechnology Transfer & Commercialization Committee
Conference Advisory Board Members:
Patrick Enright, Managing Director, Longitude Capital
Turner Jenkins, Associate, Pappas Ventures
Joel Kirschbaum, Director, UCSF
David Lewin, Senior Associate Director of Licensing, Yale University
Jonathan Lourie, Partner, Edwards Wildman Palmer
Benjamin Martin, Member, Epstein Becker Green
Nina Kjellson, General Partner, InterWest
Christopher K. Mirabelli, HealthcareVentures
Dushyant Pathak, Associate Vice Chancellor, Office of Research,
University of California, Davis
Ben Perkins, Group Head, US Life Sciences M&A, Ernst & Young
Keld Sorensen, Senior Manager, Siemens Healthcare Diagnostics
We look forward to seeing you at the conference!
|
|
SPONSORS |
 |
|
|
MEDIA PARTNERS |
 |
|
What Past
Delegates said:
“Excellent meeting that provided a thorough immersion into the fundamental and
leading thoughts in modern drug development. A must for anyone involved in drug
discovery/development."
- Santosh Kesari, MD, PhD, Director, UCSD Neuro-oncology.
“The eclectic mix of business leaders and academic scientists highlighted the
need for closer attention to the growing role of universities as virtual R&D for
not just early stage biotechs but also mid-level life science companies. The
importance of training the next generation of scientists in good business
practices during their university days was made abundantly clear.”
- Glenn D. Prestwich, PhD, Presidential Professor of Medicinal Chemistry and
Director, Entrepreneurial Faculty Scholars, University of Utah
GTC conferences consistently draw high-level and well-known speakers from
academia, government and industry to present the most up to date research and
developments in the field. Their conferences not only provide excellent food and
customer services, but they also select convenient locations that facilitate
networking and related-business and recreational activities. I participate in
their conferences annually and look forward to the next conference." - Michael
D. West, Ph.D., CEO, BioTime, Inc.
“GTC is an excellent conference organizer and is very much a part of our
marketing strategy at RBM. We’ve made a commitment to participate in several
meetings this year as we’ve found the conferences to be well aligned with our
business”
- Robert L Bencher, Director, RBM
|
|
